Actively Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
Led by Peking University People's Hospital · Updated on 2024-11-20
380
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The traditional neoadjuvant therapy for triple negative breast cancer is based on anthracycline, paclitaxel and carboplatin. Nowadays, immunotherapy combined with chemotherapy has become a new standard treatment, which not only benefits from pathological complete response (pCR), but also benefits from long-term survival. The standard chemotherapy combined with immunotherapy scheme recommended by the guidelines is TCb-AC combined with pabolizumab, but the complex chemotherapy scheme has the defects of long cycle and large adverse reactions, and the scheme of chemotherapy reduction has been explored. This project plans to adopt an ambispective cohort study, based on the large sample breast disease cohort database established by the breast center of Peking University People's Hospital, and retrospectively include the triple negative breast cancer patients with clinical stage T2 and above and/or lymph node positive who received neoadjuvant therapy (TCb-AC combined with immunotherapy, or TCb combined with immunotherapy) admitted to the center from January 1, 2019 to November 31, 2024. Patients of the same type from December 1, 2024 to December 31, 2028 were prospectively included. The efficacy and safety of different treatment regimens were compared.
CONDITIONS
Official Title
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with triple negative breast cancer by biopsy at Peking University People's Hospital
- Clinical stage II or III (T2 and above, and/or lymph node positive without distant metastasis)
- Received treatment and have hospitalization records at Peking University People's Hospital
- Have signed and agreed to participate in the PKUPH breast disease cohort study
You will not qualify if you...
- Lack of clinical and pathological data, including imaging and pathology results
- Diagnosis of metastatic breast cancer or bilateral breast cancer
- Participation in other anti-tumor clinical trials, including endocrine therapy and targeted therapy
- Receiving neoadjuvant treatments other than the established regimens in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
Y
yuan peng, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here